A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors.

Study ID
NCT02734004

Study type
Interventional

Study phase
Phase 1/Phase 2

Study status
Active, not recruiting

Trial Acronym

MEDIOLA

Trial Summary

The purpose of this study is to look at the effectiveness, safety, and antitumor activity of study drugs MEDI4736 in combination with olaparib (modules 1, 2, 3, 4, 5 and 7) and MEDI4736 in combination with olaparib and bevacizumab (module 6). It will also examine what happens to the study drugs in the body and investigate how well the combination between MEDI4736, olaparib and bevacizumab is tolerated.

More informations

Trial Starting Date

Mar 17,2016

Requirements

Gender All
Minimum age 18 Years
Maximum age 130 Years

Enrollement Limit

264